FAGRON overview

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 10 October 2024 – 7:00 AM CET Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2024. Key Highlights Continued topline momentum with 12.1% reported revenue growth (15.7% at CER) and 12.2% organic growth...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 August 2024 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 26 August 2024 through 30 August 2024, Fagron purchased 37,000 of its own shares at an average price of € 18.99 per share corresponding to a total amount of € 1,357,476.41. These purchases are part of the share buy-back program of up to 150,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme,...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 23 August 2024 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 19 August 2024 through 23 August 2024, Fagron purchased 34,500 of its owns shares at an average price of € 18.99 per share corresponding to a total amount of € 655,081.09. These purchases are part of the share buy-back program of up to 150,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme,...

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 1 August 2024 – 7:00 AM CET Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2024. Key Highlights Strong topline performance with 15.5% reported revenue growth (15.3% at Constant Exchange Rates (CER)) and...

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET Record revenue of €209 million in first quarter reflecting 15% topline growth Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 31 March 2024. Key Highlights Revenue growth accelerated to 15.3% reported growth (14.9% at CER) resulting in €209.2 million, supported by all regions Organic growth at CER...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 19 March 2024 – 6PM CET Disclosure notification from Mawer Investment Management Ltd. On 18 March 2024, Fagron received a notification pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from Mawer Investment Management Ltd. that its shareholding crossed the 5% disclosure threshold as the result of the acquisition of voting securities or voting rights on 15 March...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 14 March 2024 – 6:30 PM CET Fagron publishes annual report 2023 Fagron, the leading global player in pharmaceutical compounding, today publishes its annual report 2023. Discussion of the annual report and the approval of the financial statements will be put on the agenda of the annual general meeting of shareholders scheduled for 13 May 2024. The annual report is available in the official Dutch version and in English...